Items tagged with Medicines
How 3Ps can deliver new drugs for world's biggest killer (post)
Imagine a disease that is the world’s biggest killer, with 1.5 million people dying from it each year. It is a disease that touches every country, but some, such as South Africa, Uzbekistan and India, have been hit particularly hard. This disease has a treatment which, in its simplest form, takes six months to complete. For the complex forms, treatment causes patients to become psychotic, attempt suicide, or permanently lose their hearing due to side effects and offers a 50 percent chance of cure at best; yet in the past 50 years, only two new drugs have been developed to treat a disease that many think is extinct. The disease? Tuberculosis.
EMA: Development of medicines to treat TB (post)
The European Medicines Agency (EMA) has launched a public consultation on revised guidance on the development of new medicines to treat tuberculosis (TB). The guidance is an addendum to EMA’s guideline on the evaluation of medicines to treat bacterial infections.
Collaborations Pharma, Inc. and Rutgers announce NIH award to develop treatments for TB (post)
Fuquay-Varina, North Carolina, August 16 – The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded $149,388 to Collaborations Pharma, Inc. (CPI) to initiate a partnership with Rutgers aimed at developing a series of compounds for treating tuberculosis (TB), an infectious disease generally affecting the lungs in humans and caused by the bacterium Mycobacterium tuberculosis (Mtb).
Launch of a new web based pharmacovigilance system called PViMS (post)
The US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program, implemented by Management Sciences for Health, has launched a new, web-based pharmacovigilance management system called PViMS. PViMS enables health programs in low- and middle-income countries to follow recent World Health Organization (WHO) recommendations for implementing active drug safety monitoring and management (aDSM) when introducing new tuberculosis (TB) drugs and novel regimens.
Mouse studies show experimental TB treatment may do more harm than good (post)
Johns Hopkins researchers report evidence from mouse studies that a “repurposed” drug that would be expected to improve the immune system response of tuberculosis patients may be increasing resistance to the antibiotic drugs these patients must also take.
Scientists identify new target for TB drug development (post)
Scientists led by Dr Luiz Pedro Carvalho at the Francis Crick Institute in London have found a promising new target in the search for new tuberculosis drugs. In the process, they say they've proven the strengths of a new research technique called metabolomics.
Antibiotics developed in 1960s show promise for TB therapy (post)
First generation cephalosporins—antibiotics introduced as a treatment against bacterial infections in 1963—now show promise for tuberculosis (TB) therapy, according to new research published in Scientific Reports.
TB drug disrupted by botanical supplement, can lead to development of disease (post)
COLUMBIA, Mo. – Botanical supplements are used by people around the world to treat a wide range of physical and mental ailments. Some of these botanical supplements have high levels of antioxidants, which may have some positive health effects for certain conditions. However, a new study from the University of Missouri in partnership with scientists in Africa has uncovered evidence that these supplements and their antioxidants may reduce the effectiveness of prescription medications. The researchers examined the effects of a widely used African botanical supplement, called Sutherlandia, and found that it may disrupt the effectiveness of a common anti-tuberculosis drug. This could lead to the development of active tuberculosis and perhaps drug resistant forms of the pathogen in some patients.
New TB compound to be developed for Pan-TB regimen (post)
During the 47th Union World Conference on Lung Health, Otsuka Pharmaceutical, the manufacturer of delamanid, announced the development of a second anti-TB compound in its portfolio currently in Phase 1 clinical development. The compound, OPC-167832, is intended to target both drug-susceptible as well as drug-resistant forms of TB, and has a different mechanism of action than all currently approved anti-TB drugs.
Researchers advance treatment of TB by targeting new enzyme (post)
Researchers at Johns Hopkins report they have laid the foundation to develop novel antibiotics that work against incurable, antibiotic-resistant bacteria like tuberculosis by targeting an enzyme essential to the production and integrity of bacterial cell walls.
Page 5 of 19 · Total posts: 0
←First 4 5 6 Last→